Ventured Growth with Hercules Capital · Hercules Capital

#29 – Endpoints News: Predictions for Biotech in 2024 and Beyond | John Carroll

·46 min·4 clips

A 45-year veteran biopharma journalist admits even he was stunned by the GLP-1 revolution.

John Carroll joins the show with a long view of biopharma. As the co-founder of Endpoints News and a prize-winning journalist with 45 years of reporting experience, including more than two decades specializing in biopharma, he brings historical memory to a field that often acts as if every cycle is brand new. The conversation starts with background. Carroll's career path, his focus on biopharma, and the way his reporting has been quoted by outlets like The New York Times, The New Yorker, Financial Times, The Times of London, and Time Magazine all help explain why his perspective matters. The 2023 market reset comes up early. He explains that biotech has always moved through familiar waves of excitement, disappointment, and recovery, using examples like Alzheimer's drug optimism and even the railroads of the nineteenth century to show how hype tends to run ahead of reality before the field has to rebuild. That pattern is not treated as a flaw. Instead, he frames it as a normal part of innovation, where attention surges, expectations climb, and then the practical limits of science and development bring things back into focus. GLP-1 therapy becomes a major turning point. Carroll says he was stunned, and maybe should not have been, by how central semaglutide and the wider GLP-1 space became once the first drug reached the market. The interview also keeps returning to AI. Rather than treating AI as a buzzword, the discussion places it inside the real mechanics of drug development and the broader question of what it can actually change for biopharma companies. Asia gets its own lane. The episode points toward the future of biotech in Asia while keeping the focus on the business side of the industry rather than on geography alone. Big pharma dealmaking is part of the frame. Those transactions sit alongside the year's other surprises, giving the listener a sense of how capital, strategy, and scientific promise move together. Hope is a recurring theme. Carroll argues that people remain in biotech because the field can still feel like a place where meaningful change is possible, even when the cycle turns cautious. The closing stretch widens the lens. The conversation lands on the importance of human stories, because science becomes easier to grasp when it is translated into examples that people can understand and carry home with them.

As heard by us

John Carroll tracks biotech's hype cycle, GLP-1 momentum, and the questions shaping 2023 to 2024 with a veteran biopharma reporter's eye.

John Carroll frames biotechnology through its familiar boom-and-bust rhythm, using the 2023 to 2024 window to sort what looks durable from what still feels overheated.

Read the full review in PlayNext →

Why you'd press play

Use this to hear 2023 biopharma surprises turn into 2024 expectations.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Ventured Growth with Hercules Capital